San Francisco, California – FibroGen, Inc. recently held its Q3 2024 Earnings Conference Call on November 12th at 5:00 PM ET. During the call, key company executives and analysts discussed the company’s financial and business performance for the third quarter of 2024.

David DeLucia, the VP of Corporate FP&A & IR at FibroGen, was on hand to lead the call. Also in attendance were CEO Thane Wettig, CFO Juan Graham, and Senior VP of China Operations, Chris Chung. The discussion revolved around FibroGen’s collaborations with AstraZeneca and Astellas, financial guidance, clinical trial results, regulatory strategies, research and development activities, commercial outcomes, and overall business risks.

Throughout the call, DeLucia emphasized the importance of forward-looking statements and the potential risks and uncertainties that could impact FibroGen’s future results. The company remains committed to transparency and compliance, regularly updating stakeholders on any developments that may affect its operations or financial standing.

Analysts and investors participating in the conference call had the opportunity to ask questions and gain further insights into FibroGen’s performance. This interactive session allowed for a deeper understanding of the company’s strategies and goals moving forward.

FibroGen’s dedication to innovation and growth in the pharmaceutical industry was a cornerstone of the discussions during the Q3 2024 Earnings Conference Call. By sharing updates on key partnerships and clinical trial progress, the company demonstrated its commitment to advancing healthcare solutions and driving positive outcomes for patients worldwide.

As the conference drew to a close, attendees were reminded of the importance of staying informed about FibroGen’s activities and financial outlook. With an eye toward the future, the company remains focused on delivering value to its shareholders and making a meaningful impact in the healthcare sector.